Prudential Financial Inc. Lowers Stake in Supernus Pharmaceuticals, Inc. (SUPN)
Prudential Financial Inc. decreased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 17.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 225,190 shares of the specialty pharmaceutical company’s stock after selling 48,409 shares during the period. Prudential Financial Inc. owned about 0.45% of Supernus Pharmaceuticals worth $7,048,000 at the end of the most recent reporting period.
Other institutional investors have also recently modified their holdings of the company. Ameritas Investment Partners Inc. purchased a new position in shares of Supernus Pharmaceuticals during the first quarter worth approximately $127,000. Pacad Investment Ltd. purchased a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $124,000. Fortaleza Asset Management Inc. purchased a new position in shares of Supernus Pharmaceuticals during the first quarter worth approximately $160,000. State of Alaska Department of Revenue increased its position in shares of Supernus Pharmaceuticals by 3.2% in the first quarter. State of Alaska Department of Revenue now owns 5,530 shares of the specialty pharmaceutical company’s stock worth $173,000 after buying an additional 170 shares during the last quarter. Finally, First Citizens Bank & Trust Co. purchased a new position in shares of Supernus Pharmaceuticals during the first quarter worth approximately $208,000. Hedge funds and other institutional investors own 92.17% of the company’s stock.
Supernus Pharmaceuticals, Inc. (SUPN) opened at 38.65 on Friday. The firm has a market cap of $1.94 billion, a P/E ratio of 20.79 and a beta of 1.76. The company’s 50 day moving average is $35.55 and its 200-day moving average is $29.14. Supernus Pharmaceuticals, Inc. has a 52 week low of $17.25 and a 52 week high of $41.35.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.22 by $0.03. The firm had revenue of $57.58 million for the quarter, compared to analysts’ expectations of $57.91 million. Supernus Pharmaceuticals had a return on equity of 31.79% and a net margin of 42.46%. Equities analysts expect that Supernus Pharmaceuticals, Inc. will post $1.08 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: This story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this story on another publication, it was copied illegally and reposted in violation of US and international copyright and trademark law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/06/18/prudential-financial-inc-lowers-stake-in-supernus-pharmaceuticals-inc-supn.html.
A number of equities analysts recently commented on the stock. Piper Jaffray Companies upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $30.00 to $44.00 in a research note on Thursday, June 1st. Jefferies Group LLC boosted their target price on shares of Supernus Pharmaceuticals from $35.00 to $45.00 and gave the stock a “buy” rating in a research note on Wednesday, May 31st. Zacks Investment Research upgraded shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Saturday, March 4th. Cowen and Company boosted their target price on shares of Supernus Pharmaceuticals from $31.00 to $34.00 and gave the stock an “outperform” rating in a research note on Thursday, May 11th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $31.00 target price on shares of Supernus Pharmaceuticals in a research note on Tuesday, March 7th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $33.43.
In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 54,000 shares of the firm’s stock in a transaction on Monday, April 24th. The shares were sold at an average price of $32.37, for a total transaction of $1,747,980.00. Following the completion of the transaction, the chief financial officer now directly owns 54,221 shares of the company’s stock, valued at approximately $1,755,133.77. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 5,500 shares of the firm’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $34.90, for a total transaction of $191,950.00. Following the transaction, the vice president now directly owns 43,887 shares of the company’s stock, valued at $1,531,656.30. The disclosure for this sale can be found here. Over the last three months, insiders have sold 83,806 shares of company stock valued at $2,813,038. 6.70% of the stock is owned by company insiders.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.